Get the Stockscreener App
32.16
0.92%
-0.30
Tg Therapeutics Inc stock is traded at $32.16, with a volume of 2.39M.
It is down -0.92% in the last 24 hours and up +18.58% over the past month.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
See More
Previous Close:
$32.46
Open:
$32.29
24h Volume:
2.39M
Relative Volume:
1.14
Market Cap:
$5.10B
Revenue:
$264.79M
Net Income/Loss:
$-14.36M
P/E Ratio:
-292.36
EPS:
-0.11
Net Cash Flow:
$-28.11M
1W Performance:
-0.16%
1M Performance:
+18.58%
6M Performance:
-13.62%
1Y Performance:
+38.68%
1-Day Range:
$31.58
$32.56
1-Week Range:
$31.05
$32.57
52-Week Range:
$21.16
$46.48
Tg Therapeutics Inc Stock (TGTX) Company Profile
Name
Tg Therapeutics Inc
Sector
Industry
Phone
(212) 554-4484
Address
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Compare TGTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
32.16 | 5.05B | 264.79M | -14.36M | -28.11M | -0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Neutral |
| Oct-29-24 | Initiated | TD Cowen | Buy |
| Aug-02-23 | Upgrade | Goldman | Sell → Neutral |
| Jun-26-23 | Resumed | Jefferies | Buy |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Nov-15-21 | Downgrade | Goldman | Neutral → Sell |
| Apr-20-21 | Initiated | Goldman | Neutral |
| Apr-19-21 | Reiterated | H.C. Wainwright | Buy |
| Sep-01-20 | Initiated | JP Morgan | Overweight |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Initiated | Evercore ISI | Outperform |
| Jan-17-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Feb-06-19 | Resumed | Jefferies | Buy |
| Sep-25-18 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-09-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-01-17 | Resumed | B. Riley FBR, Inc. | Buy |
| Nov-14-17 | Resumed | H.C. Wainwright | Buy |
| Apr-25-17 | Initiated | Jefferies | Buy |
| Mar-06-17 | Reiterated | FBR & Co. | Outperform |
| Oct-06-16 | Resumed | Brean Capital | Buy |
| May-27-16 | Initiated | SunTrust | Buy |
| Dec-01-15 | Initiated | FBR Capital | Outperform |
| Sep-09-15 | Initiated | Raymond James | Strong Buy |
| Aug-12-15 | Resumed | H.C. Wainwright | Buy |
| Jun-19-15 | Reiterated | Brean Capital | Buy |
| Dec-11-14 | Reiterated | ROTH Capital | Buy |
| Dec-10-14 | Reiterated | ROTH Capital | Buy |
View All
Tg Therapeutics Inc Stock (TGTX) Latest News
Cinctive Capital Management LP Purchases Shares of 14,145 TG Therapeutics, Inc. $TGTX - MarketBeat
October 31st Options Now Available For TG Therapeutics (TGTX) - Nasdaq
TG Therapeutics falls after Q2 miss despite guidance raise - MSN
TG Therapeutics Announces Schedule of Data Presentations - GlobeNewswire
TG Therapeutics to Present BRIUMVI MS Drug Data at ECTRIMS 2025 | TGTX Stock News - Stock Titan
Banque Transatlantique SA Acquires Shares of 15,468 TG Therapeutics, Inc. $TGTX - MarketBeat
Can TG Therapeutics Inc. Escape Recent Bear ChannelJuly 2025 Movers & Fast Gain Stock Tips - beatles.ru
TG Therapeutics begins phase 3 trial of subcutaneous MS treatment By Investing.com - Investing.com South Africa
TG Therapeutics at H.C. Wainwright: Strategic Moves in RMS Market By Investing.com - Investing.com Canada
TGTX Launches Phase 3 Trial for Subcutaneous BRIUMVI in Multiple Sclerosis - GuruFocus
TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment - The Manila Times
TG announces phase 3 trial for subcutaneous Briumvi commenced enrollment - MarketScreener
TG Therapeutics begins phase 3 trial of subcutaneous MS treatment - Investing.com
TG Therapeutics Begins Enrollment in Phase 3 Trial for Subcutaneous BRIUMVI in Patients with Relapsing Multiple Sclerosis - Quiver Quantitative
40% Market Opportunity: TG Therapeutics Tests At-Home MS Treatment in Phase 3 BRIUMVI Trial - Stock Titan
Why TG Therapeutics, Inc. (TGTX) Surged On Monday? - MSN
TG Therapeutics (NASDAQ:TGTX) Shares Gap UpShould You Buy? - MarketBeat
Will TG Therapeutics Inc. stock go up in YEARM&A Rumor & Breakout Confirmation Trade Signals - 강소기업뉴스
Why TG Therapeutics (TGTX) Is Up 9.8% After Launching Another $100 Million Buyback Program - Yahoo Finance
Is TG Therapeutics Inc. stock reversal real or fakePortfolio Value Report & Consistent Income Trade Recommendations - Newser
TG Therapeutics, Inc. $TGTX Shares Sold by 683 Capital Management LLC - MarketBeat
Is it too late to sell TG Therapeutics Inc.2025 Top Gainers & Fast Moving Stock Trade Plans - Newser
Is TG Therapeutics Inc. building a consolidation baseTrade Analysis Summary & Daily Profit Focused Stock Screening - Newser
Analyzing net buyer seller activity in TG Therapeutics Inc.Market Activity Recap & Verified Entry Point Signals - Newser
Is TG Therapeutics Inc. affected by consumer sentimentJuly 2025 Breakouts & High Accuracy Investment Signals - خودرو بانک
Can TG Therapeutics Inc. sustain its profitabilityCPI Data & Community Verified Watchlist Alerts - خودرو بانک
Using RSI to spot recovery in TG Therapeutics Inc.July 2025 Fed Impact & AI Driven Price Forecasts - Newser
Comparing TG Therapeutics Inc. in custom built stock radarsEarnings Overview Summary & Stock Portfolio Risk Management - Newser
Ranking TG Therapeutics Inc. among high performing stocks via toolsNew Guidance & Low Risk Entry Point Tips - Newser
What recovery options are there for TG Therapeutics Inc.Weekly Gains Report & Fast Exit and Entry Trade Guides - Newser
Can TG Therapeutics Inc. outperform in the next rallyTrade Analysis Report & Community Trade Idea Sharing Platform - خودرو بانک
Using Python tools to backtest TG Therapeutics Inc. strategiesJuly 2025 Pullbacks & AI Forecasted Entry and Exit Points - Newser
Has TG Therapeutics Inc. formed a bullish divergence2025 AllTime Highs & Consistent Return Investment Signals - Newser
Why TG Therapeutics Inc. is moving todayWeekly Trade Summary & Safe Entry Momentum Tips - Newser
Using AI based signals to follow TG Therapeutics Inc.Weekly Trend Recap & Daily Profit Maximizing Trade Tips - Newser
Using fundamentals and technicals on TG Therapeutics Inc.2025 Momentum Check & Expert Verified Movement Alerts - Newser
Published on: 2025-09-05 02:02:16 - Newser
How cyclical is TG Therapeutics Inc.’s revenue streamCEO Change & Weekly Stock Performance Updates - 뉴스영
News impact scoring models applied to TG Therapeutics Inc.2025 Retail Activity & Fast Gain Swing Trade Alerts - Newser
Using data tools to time your TG Therapeutics Inc. exitPortfolio Value Report & Stock Portfolio Risk Control - Newser
Real time social sentiment graph for TG Therapeutics IncWeekly Risk Summary & Precise Buy Zone Tips - Newser
What’s the recovery path for long term holders of TG Therapeutics Inc.Trade Risk Report & Daily Profit Maximizing Tips - Newser
Sector ETF performance correlation with TG Therapeutics Inc.Market Risk Analysis & Low Risk High Reward Trade Ideas - Newser
TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewswire
TG Therapeutics CEO to Participate in H.C. Wainwright Global Investment Conference. - AInvest
Biotech Leader TG Therapeutics Featured at H.C. Wainwright Global Investment Conference 2025 - Stock Titan
TG Therapeutics: Strategic Innovations and Market Expansion as Catalysts for Investor Optimism - AInvest
Transcript : TG Therapeutics, Inc. Presents at Cantor Global Healthcare Conference 2025, Sep-03-2025 10 - MarketScreener
Should you wait for a breakout in TG Therapeutics Inc.2025 Market Trends & Risk Adjusted Swing Trade Ideas - Newser
How institutional ownership impacts TG Therapeutics Inc. stockQuarterly Market Summary & Weekly Stock Breakout Alerts - Newser
774,656 Shares in TG Therapeutics, Inc. $TGTX Acquired by Driehaus Capital Management LLC - MarketBeat
Tg Therapeutics Inc Stock (TGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):